Intelligent Vaginal Health Management Systems
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates Lactobacillus paracasei MG4272 strain with AI, IoT, blockchain, and nanomaterials to create a holistic, personalized, and adaptive system for vaginal health management, providing real-time monitoring, diagnosis, and treatment.
Background and Problem Solved
The original patent disclosed a composition comprising a cell-free supernatant of Lactobacillus paracasei MG4272 strain, which has antifungal and antimicrobial activities. However, the patent did not address the need for a comprehensive system that can monitor, diagnose, and treat vaginal infections in a personalized and adaptive manner. The present inventive concept solves this problem by integrating the Lactobacillus paracasei MG4272 strain with advanced technologies to provide a synergistic solution.
Detailed Description of the Inventive Concept
The inventive concept comprises a Lactobacillus paracasei MG4272 strain-based composition, an AI-powered monitoring module, an IoT-enabled vaginal ring, a blockchain-based tracking system, and a machine learning algorithm for predicting infection likelihood. The system receives input from a user's wearable device, provides personalized recommendations, and adjusts the composition's release based on the user's body temperature and pH levels. The nanomaterial-based delivery system ensures targeted release of the supernatant. The biosensor is integrated with an AI-powered diagnostic module, providing real-time results to a user's mobile device.
Novelty and Inventive Step
The integration of Lactobacillus paracasei MG4272 strain with AI, IoT, blockchain, and nanomaterials is novel and non-obvious, as it creates a holistic system that can monitor, diagnose, and treat vaginal infections in a personalized and adaptive manner. The inventive concept's synergistic combination of technologies provides a new and innovative solution that is not obvious from the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include varying the type of AI algorithm used, incorporating additional sensors or tracking systems, or using different nanomaterials for delivery. Variations may include adapting the system for use in different populations or for treating different types of infections.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the women's health and wellness market, particularly in the areas of vaginal health management, infection prevention, and personalized medicine. The market for vaginal health products is expected to grow, and the present inventive concept is well-positioned to capitalize on this trend.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Microbiology, Biotechnology, and Medical Device Technologies with a specialization in Probiotic Compositions and Digital Health Monitoring Systems
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in microbiology or bioengineering, familiar with probiotic strain characterization, digital health technologies, and medical device integration, possessing knowledge of AI, IoT, and nanomaterial delivery systems
Obviousness Rationale
A person having ordinary skill in the art would recognize that integrating digital monitoring technologies with a known probiotic strain represents a predictable application of existing technological capabilities. The source patent's specific Lactobacillus paracasei MG4272 strain provides a well-characterized biological foundation that naturally invites technological augmentation for enhanced health monitoring and treatment. The combination of known probiotic characteristics with emerging digital health technologies reflects a logical progression of medical diagnostic and treatment approaches.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,580 |
|---|---|
| Title | Lactobacillus having antimicrobial effect on Gardnerella vaginalis and Candida albicans |
| Assignee(s) | Mediogen Co., Ltd. |